These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31820674)

  • 1. Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials.
    Nomura S; Shinozaki T; Hamada C
    J Biopharm Stat; 2020 Mar; 30(2):377-401. PubMed ID: 31820674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
    Nomura S; Hirakawa A; Hamada C
    J Biopharm Stat; 2018; 28(4):589-611. PubMed ID: 28886305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A class of Covariate-Adjusted Response-Adaptive Allocation Designs for Multitreatment Binary Response Trials.
    Biswas A; Bhattacharya R
    J Biopharm Stat; 2018; 28(5):809-823. PubMed ID: 29913107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New designs for basket clinical trials in oncology.
    Simon R
    J Biopharm Stat; 2018; 28(2):245-255. PubMed ID: 28877003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.
    Jönsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jönsson B; Weinstein MC; Drummond M
    Value Health; 2014 Sep; 17(6):707-13. PubMed ID: 25236994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
    Zhu H
    J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Power and sample size for randomized phase III survival trials under the Weibull model.
    Wu J
    J Biopharm Stat; 2015; 25(1):16-28. PubMed ID: 24895942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive survival trials.
    Rosenberger WF; Seshaiyer P
    J Biopharm Stat; 1997 Nov; 7(4):617-24. PubMed ID: 9358333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A causal modelling framework for reference-based imputation and tipping point analysis in clinical trials with quantitative outcome.
    White IR; Joseph R; Best N
    J Biopharm Stat; 2020 Mar; 30(2):334-350. PubMed ID: 31718423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial.
    Markman M
    Curr Oncol Rep; 2004 Nov; 6(6):421-2. PubMed ID: 15485610
    [No Abstract]   [Full Text] [Related]  

  • 15. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
    Jiménez JL; Stalbovskaya V; Jones B
    Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted survival improvements in clinical trials: are you an absolutist or relativist?
    Paul J
    Cancer; 2015 Feb; 121(3):335-8. PubMed ID: 25278175
    [No Abstract]   [Full Text] [Related]  

  • 17. New designs for the selection of treatments to be tested in randomized clinical trials.
    Simon R; Thall PF; Ellenberg SS
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase III trials in oncology].
    Imadalou K; Cvitkovic E
    Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous use of weighted logrank and standardized Kaplan-Meier statistics.
    Yang P; Fleming TR
    J Biopharm Stat; 2006; 16(2):241-52. PubMed ID: 16584070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive sequential testing for multiple comparisons.
    Gao P; Liu L; Mehta C
    J Biopharm Stat; 2014; 24(5):1035-58. PubMed ID: 24926848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.